<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="810">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00189306</nctid>
  <trial_identification>
    <studytitle>Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream</studytitle>
    <scientifictitle>An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1413-IMIQ</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Superficial Basal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Imiquimod 5% cream

Experimental: Aldara - Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks


Treatment: drugs: Imiquimod 5% cream
Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC) - Number of participants clinically clear of superficial basal cell carcinoma at the treated target tumor site at the 12-week posttreatment visit (ie, initial clearance rate) who remain clear during a 5 year follow-up period.</outcome>
      <timepoint>5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Cleared of Superficial Basal Cell Carcinoma at 12 Weeks - Number of participants cleared at 12 weeks(the number of subjects with no clinical evidence of superficial basal cell carcinoma at the target tumor site at the 12-week posttreatment visit)</outcome>
      <timepoint>12 week posttreatment visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have at least 1 previously untreated superficial basal cell carcinoma tumor

          -  Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of clinically significant, unstable medical conditions

          -  Cannot have recent use of topical steroids or retinoids in the treatment area.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>169</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Medical Centre, Concord Hospital - Concord</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Skin Centre - Benowa</hospital>
    <hospital>South East Dermatology Centre - Carina Heights</hospital>
    <hospital>105 Fulham Road - Gulliver</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Flinders Medical Center - Bedford Park</hospital>
    <hospital>Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Western Hospital - Footscray</hospital>
    <hospital>Austin &amp; Repartriation Hospital - Heidelburg</hospital>
    <hospital>Freemantle Dermatology - Fremantle</hospital>
    <hospital>158 South Terrace - Perth</hospital>
    <hospital>Subiaco Clinic - Subiaco</hospital>
    <postcode> - Concord</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - Benowa</postcode>
    <postcode> - Carina Heights</postcode>
    <postcode> - Gulliver</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Woodville</postcode>
    <postcode> - Footscray</postcode>
    <postcode> - Heidelburg</postcode>
    <postcode> - Fremantle</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Takapuna</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Graceway Pharmaceuticals, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied
      topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of
      follow-up.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00189306</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jim Lee, Dr.</name>
      <address>Graceway Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>